A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.